ID: ALA4636054

Max Phase: Preclinical

Molecular Formula: C17H16F2N4O4

Molecular Weight: 378.34

Molecule Type: Unknown

Representations

Canonical SMILES:  Nc1ncnn2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)cc(-c3ccc(F)cc3F)c12

Standard InChI:  InChI=1S/C17H16F2N4O4/c18-7-1-2-8(10(19)3-7)9-4-11(23-13(9)17(20)21-6-22-23)16-15(26)14(25)12(5-24)27-16/h1-4,6,12,14-16,24-26H,5H2,(H2,20,21,22)/t12-,14-,15-,16+/m1/s1

Standard InChI Key:  XCVFQTFAGIWYAN-MIGQKNRLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 378.34

Molecular Weight (Monoisotopic): 378.1140

AlogP: 0.41

#Rotatable Bonds: 3

Polar Surface Area: 126.13

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.71

CX Basic pKa: 0.56

CX LogP: 0.29

CX LogD: 0.29

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.52

Np Likeness Score: 0.01

References

1. Li Q, Groaz E, Persoons L, Daelemans D, Herdewijn P..  (2020)  Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.,  11  (8): [PMID:32832030] [10.1021/acsmedchemlett.0c00269]

Source

Source(1):

• Scientific Literature